Study confirms Sensoril is fast-acting, experiential

Natreon Inc. and NutraGenesis LLC are pleased to announce publication of a new study on Sensoril® that demonstrated Sensoril’s ability to provide resistance to physical stress in a fast-acting, experiential manner. The randomized, double-blind, placebo-controlled, crossover human clinical trial evaluated study subjects for their resistance to heat stress and pain using a well-studied, validated model.

The study published in the peer-reviewed Research Journal of Life Sciences May 2013 issue reported that a single dose of Sensoril provided a 12.85 percent increase in resistance to pain from a physical stress three hours after consumption. The results were highly significant (p≤0.001) and show in a clinical model how quickly Sensoril’s adaptogenic benefits can be experienced. The study was conducted by researchers at the Department of Clinical Pharmacology and Therapeutics at the NIZAMS Institute of Medical Sciences in Hyderabad, India.

In addition to the news of this most recent publication, Natreon and NutraGenesis are announcing that Sensoril’s specifications have been recently modified. Sensoril features the highest levels of adaptogenic glycowithanolide bioactives in the industry. In fact, after years of consistent, high potency resulting from Sensoril’s multi-patented extraction process, the standardization level for these bioactives in Sensoril was recently increased by 25 percent from a minimum of 8 percent to a minimum of 10 percent glycowithanolides. The withaferin A standardization level was also modified from a maximum of 2 percent to 0.5 percent.

“We are delighted with the results of this study and the compelling data which this research has revealed about Sensoril’s ability to be fast acting” says Dr. Sanni Raju, CEO and chairman of the board of Natreon Inc. “Our commitment to building the research and intellectual property platform for Sensoril on behalf of our customers and partners has and always will be our first priority”.

Suzanne McNeary, president of NutraGenesis, LLC, the exclusive licensee for Sensoril in North America, added, “the results of this new study and the modification of the product specifications further solidify Sensoril’s superiority in the ashwagandha marketplace. As the most concentrated, multi-patented, truly full-spectrum ashwagandha extract with over a decade of safe and efficacious use in the industry, it’s the reason that Sensoril is the number one choice in ashwagandha extracts of fine dietary supplement brands around the world”.